Prevention of Colorectal Cancer Through Multiomics Blood Testing

Prior treatment

• Participated or currently participating in a clinical research study in which an experimental medication has been administered during the 60 days up to and including the date of providing informed consent or may be administered through the time of the colonoscopy

Other illness

• Known hereditary gastrointestinal cancer syndrome (for example, hereditary non-polyposis CRC syndrome (HNPCC) or Lynch syndrome, or familial adenomatous polyposis (FAP)
• Personal history 2.1 CRC or colorectal adenoma 2.2 Inflammatory bowel disease (IBD), including chronic ulcerative colitis (CUC) and crohn's disease (CD) 2.3 Colonoscopy in the 9 years preceding enrollment 2.4 Stool DNA testing in the 2 years preceding enrollment 2.5 Symptoms of lower gastrointestinal tract disease warranting colonoscopic evaluation
• A medical condition which, in the opinion of the Investigator, should preclude enrollment in the study

• 45-85 years of age
• Willing to undergo a standard-of-care screening colonoscopy
• Able and willing to provide a blood sample
• Able and willing to sign informed consent